AACR 2023 | Can personalized mRNA vaccines be applicable in lung cancer?

Pasi Jänne, MD, PhD, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA, comments on his highlights presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, including findings from the KEYNOTE-942 trial (NCT03897881), which assessed a personalized mRNA vaccine with a checkpoint inhibitor in patients with melanoma. The technology has potential to be used in other cancers such as lung cancer, but more genomic analysis and tests are needed. This interview took place at the AACR Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.